New Life Ventures Announces Leadership Transition at CryoBios
For Immediate Release
New Life Ventures today are happy to announce a leadership change at CryoBios, the life extension company in which it recently invested as part of its mission to help humanity transcend its biological limitations.
Effective immediately, Dr. Beatrice Heimer will be departing from her role as Chief Executive Officer of CryoBios. This decision follows the company’s discovery of previously undisclosed matters that were inconsistent with the transparency and governance standards to which both New Life Ventures and CryoBios are committed. While we recognize Dr. Heimer’s pioneering contributions to cryonic research and her role in establishing CryoBios as a leader in the field, it is imperative that our leadership reflects the highest levels of integrity and openness.
In the interim, Alex Davert, strategic advisor to CryoBios and consultant with New Life Ventures, will serve as Acting CEO. Mr. Davert will oversee ongoing operations, ensure continuity of services for our clients worldwide, and work closely with the CryoBios leadership team to reinforce the company’s commitment to ethical innovation.
“CryoBios’s mission is bigger than any one individual,” said Mr. Davert. “Our clients trust us with their future, and that trust rests on an unshakable foundation of ethical practice. I look forward to guiding the team through this transition and strengthening that foundation.”
CryoBios remains dedicated to offering swift, secure cryostasis solutions for individuals seeking to preserve their agency in the face of time, in partnership with accredited medical facilities in Switzerland and beyond. This leadership change represents an opportunity to recommit ourselves to the principles that define our vision: integrity, innovation, and the pursuit of a future worth living.